Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pharmacotherapeutic management of bipolar disorder has advanced considerably since the introduction of lithium therapy nearly 50 years ago. The sizable percentage of patients who do not respond adequately to lithium and/or are intolerant to its side effects has served as an impetus for identifying alternative pharmacotherapeutic agents. Recent advances in the understanding of the neurotransmitter systems and their receptors as it applies to treatment of bipolar disorder has, in part, led to progress in delineating applications of anticonvulsant/antiepileptic drugs (AEDs) in this area. Although the efficacy of many drugs has been evaluated in patients with this disorder, medication tolerability and adherence issues related to unfavorable side effect profiles are substantial impediments to the development of novel pharmacotherapies. The potential for excessive weight gain as a side effect of certain psychopharmacologic agents remains a concern to both clinicians and patients. METHOD: English-language literature from 1985-2001 in MEDLINE was searched for the terms bipolar disorder, anticonvulsant, antiepileptic, lithium, antipsychotic, weight, and compliance. This article reviewed current therapeutic options for bipolar disorder, including newer AEDs and atypical antipsychotic drugs, with emphasis on the issue of weight gain and possible approaches to minimizing this risk. RESULTS: Certain newer AEDs are characterized by more favorable safety and tolerability profiles that include weight loss as a desirable side effect. Because bipolar disorder is associated with unacceptably high rates of relapse, recurrence, and morbidity, the concept of pharmacotherapeutic efficacy logically not only includes symptom relief but also necessarily encompasses issues related to regimen tolerability and adherence. CONCLUSION: There is a need for guidelines to help physicians carefully formulate and individualize management plans to reach safe, effective, and cost-efficient patient outcomes. Monitoring the weight of patients with bipolar disorder and educating them regarding this issue should be standard components of any treatment plan.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The medications most commonly associated with weight gain are olanzapine, clozapine, risperidone, quetiapine, gabapentin, divalproex and lithium; with carbamazepine, lamotrigine, and ziprasidone being the safer or options associated with less weight gain.808”
Citations
Cites
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Kuczmarski, R. J. (1994) · JAMA · doi:10.1001/jama.272.3.205 · Cited by 2,362
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Tohen, M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
Calabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1106 · Cited by 498
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446
Gabapentin in bipolar disorder: a placebo‐controlled trial of adjunctive therapy1
Pande, A. C., Crockatt, J. G., Janney, C. A., Werth, J. L., Tsaroucha, G., & Gabapentin Bipolar Disorder Study Group (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.20305.x · Cited by 313
Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.4.431 · Cited by 266
Cited by
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
STIGMA: BARRIER TO MENTAL HEALTH CARE AMONG ETHNIC MINORITIES
Gary, F. A. (2005) · Issues in Mental Health Nursing · doi:10.1080/01612840500280638 · Cited by 613
“Kafkaesque nightmares sometimes emerge within families as they ponder how, when, why, and under what circumstances these horrific illnesses occurred in their family members (Adshead, 2003; Anderson & Nickerson, 2005; Lefley, 1989; Nemeroff, 2003; Pinel, 1999; Szasz, 2003).”
BackgroundAsenapine: a novel psychopharmacologic agent with a unique human receptor signature
Shahid, M., Walker, G., Zorn, S., & Wong, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881107082944 · Cited by 493
Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians
Fagiolini, A., Frank, E., Scott, J. A., Turkin, S., & Kupfer, D. J. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00234.x · Cited by 449
Burden of general medical conditions among individuals with bipolar disorder
Kilbourne, A. M., Cornelius, J. R., Han, X., Pincus, H. A., Shad, M., Salloum, I., Conigliaro, J., & Haas, G. L. (2004) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00138.x · Cited by 412
Gould, T. D., Quiroz, J. A., Singh, J., Zarate, C. A., & Manji, H. K. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001518 · Cited by 238
Kushner, S. F., Khan, A., Lane, R., & Olson, W. H. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00276.x · Cited by 180
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor
Torrent, C., Amann, B., Sánchez‐Moreno, J., Colom, F., Reinares, M., Comes, M., Rosa, A. R., Scott, J., & Vieta, E. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01204.x · Cited by 169
“Weight gain in patients on lithium as prophylactic treatment was considered to be related to poor adherence in up to 50% of cases, increasing to 90% of patients having seriously considered discontinuing treatment (33, 44).”
BackgroundAtypical antipsychotics related metabolic syndrome in bipolar patients
Yumru, M., SAVAS, H. A., Kurt, E., Kaya, M., Selek, S., Savaş, E., Oral, E., & Atagün, M. İ. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.009 · Cited by 160
“bipolar disorder (BD) (Fagiolini et al., 2002; McElroy et al., 2004, 2002; Keck and McElroy, 2003; Nemeroff, 2003; Kilbourne et al., 2004; Sobczak et al., 2004; Atmaca et al., 2002).”
BackgroundPharmacological Treatments for First-Episode Schizophrenia
Robinson, D. G., Woerner, M. G., Delman, H. M., & Kane, J. M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi032 · Cited by 151
Robinson, D. G., Woerner, M. G., Napolitano, B., Patel, R. C., Sevy, S. M., Gunduz-Bruce, H., Soto-Perello, J. M., Mendelowitz, A., Khadivi, A., Miller, R., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2096 · Cited by 107
Impact of Lamotrigine and Lithium on Weight in Obese and Nonobese Patients With Bipolar I Disorder
Bowden, C. L., Calabrese, J. R., Ketter, T. A., Sachs, G. S., White, R. L., & Thompson, T. R. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1199 · Cited by 100
Aman, T. K., Shen, R., & Haj‐Dahmane, S. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111690 · Cited by 110
Psychopharmacology of topiramate: from epilepsy to bipolar disorder
Cavanna, A. E., Monaco, F., Mula, M., Robertson, M. M., & Critchley, H. (2006) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2006.2.4.475 · Cited by 95
“A few preliminary studies have reported decreased appetite or weight loss in patients treated with TPM for BD (Gordon and Price 1995; Nemeroff 2003; Woods et al 2004).”
Dols, A., Sienaert, P., van Gerven, H., Schouws, S., Stevens, A., Kupka, R., & Stek, M. L. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836435e2 · Cited by 86
“(Nemeroff, 2003), even before starting mood stabilizer therapy.”
BackgroundA Review on the Effects of Aromatherapy for Patients with Depressive Symptoms
Yim, V. W. C., Ng, A. K. Y., Tsang, H. W. H., & Leung, A. Y. (2009) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2008.0333 · Cited by 94
Xiong, M., Li, Y., Tang, P., Zhang, Y., Cao, M., Ni, J., & Xing, M. (2018) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2017.0320 · Cited by 109
Self-Reported Medication Treatment Adherence Among Veterans With Bipolar Disorder
Sajatovic, M., Bauer, M. S., Kilbourne, A. M., Vertrees, J. E., & Williford, W. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.1.56 · Cited by 83
Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder
Sachs, G. S., Bowden, C. L., Calabrese, J. R., Ketter, T. A., Thompson, T. R., White, R., & Bentley, B. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00308.x · Cited by 79
Novel treatment approaches for refractory anxiety disorders
Pollack, M. H., Otto, M. W., Roy-Byrne, P. P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · Depression and Anxiety · doi:10.1002/da.20329 · Cited by 77
“By focusing on discrete neurobiological pathways, it is hoped that anxiolytic drugs will be discovered that normalize pathological activity in brain circuits and produce fewer adverse effects, including tolerance, dependence, and withdrawal effects [Nemeroff, 2003].”
BackgroundValproic acid: how it works. Or not
Lagace, D. C., O'Brien, W. T., Gurvich, N., Nachtigal, M. W., & Klein, P. S. (2004) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2004.09.013 · Cited by 72
“VPA and other psychotropic agents also have a propensity to induce weight gain, an effect that has been the subject of many recent reviews [55–57].”
ResultAmsterdam, J. D., & Bodkin, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239794.37073.70 · Cited by 72
Safety and tolerability of emerging pharmacological treatments for bipolar disorder
Dünner, D. L. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00235.x · Cited by 74
Gentile, S. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00589.x · Cited by 61
Himmerich, H., Koethe, D., Schuld, A., Yassouridis, A., & Pollm�cher, T. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2038-9 · Cited by 60
“Numerous studies confirm that chronic treatment with lithium results in body weight gain, which is one of the primaryreasonswhypatientsstoptakinglithium( Nemeroff 2003 ).”
BackgroundBeynon, S., Soares-Weiser, K., Woolacott, N., Duffy, S., & Geddes, Jr. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093885 · Cited by 61
“Email: nw11@york.ac.uk effects of these drugs (Kusumakar, 2002; Nemeroff, 2003; Yatham, 2003; Ernst and Goldberg, 2004).”
Weber, N. S., Fisher, J. A., Cowan, D. N., & Niebuhr, D. W. (2011) · Psychiatric Services · doi:10.1176/ps.62.10.pss6210_1152 · Cited by 53
Lagace, D. C., McLeod, R. S., & Nachtigal, M. W. (2004) · Endocrinology · doi:10.1210/en.2004-0877 · Cited by 55
Metabolic Syndrome in Bipolar Disorders
Grover, S., Malhotra, N., Chakrabarti, S., & Kulhara, P. (2012) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.101767 · Cited by 48
“Information is available about the prevalence of obesity,[11-17] diabetes,[18-23] dyslipidemia,[18,24-26] and hypertension[27] in patients with BPAD, but few studies have evaluated the prevalence of MetS per se in patients of BPAD.”
BackgroundHardy, S., Hinks, P., & Gray, R. J. (2013) · Journal of Mental Health · doi:10.3109/09638237.2012.759194 · Cited by 51
“Medication used to treat schizophrenia and bipolar disorder has also been linked with an increased risk of CVD (Marder et al., 2004; Masand & Gupta, 2002; Nemeroff, 2003).”
BackgroundKetter, T. A., & Haupt, D. W. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148616 · Cited by 47
Types of information physicians provide when prescribing antidepressants
Young, H. N., Bell, R. A., Epstein, R. M., Feldman, M. D., & Kravitz, R. L. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00589.x · Cited by 44
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Marken, P. A., & Pies, R. W. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g112 · Cited by 45
Dhonnchadha, B. �. N., Ripoll, N., Cl�net, F., Hascoët, M., & Bourin, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2044-y · Cited by 43
“Even though it is now well established that selective antidepressants (ADs) possess anxiolytic properties, their underlying neuropharmacological mechanism of action is still not understood (Zohar and Westenberg 2000; Bourin and Lambert 2002; Bourin et al. 2002; Nemeroff 2003; Vaswani et al. 2003).”
BackgroundPsychogenic nonepileptic seizures are associated with an increased risk of obesity
Marquez, A. V., Farias, S. T., Apperson, M., Koopmans, S., Jørgensen, J., Shatzel, A., & Alsaadi, T. M. (2003) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.10.019 · Cited by 44
“The three anticonvulsants commonly known to cause weight gain are valproic acid (VPA), gabapentin (GBP), and vigabatrin (VGB) [33– 35].”
BackgroundThe burden of general medical conditions in patients with bipolar disorder
Kilbourne, A. M. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0069-5 · Cited by 34
Glycogen synthase kinase‐3 is required for optimal de novo synthesis of inositol
Azab, A. N., He, Q., Ju, S., Li, G., & Greenberg, M. L. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05591.x · Cited by 41
“However, these drugs are ineffective for and/or not tolerated by a significant per cent of patients (Nemeroff, 2003; Bowden, 2004; Gitlin, 2006).”
BackgroundRole of Adverse Effects in Medication Nonadherence in Bipolar Disorder
Mago, R., Borra, D., & Mahajan, R. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000017 · Cited by 33
“Weight gain is less of a concern with carbamazepine, lamotrigine, and ziprasidone, whereas topiramate may be associated with weight loss.(23) Twenty percent of patients on lithium reported a weight gain of over ten kilograms.”
BackgroundAtypical mood stabilizers: a ‘typical’ role for atypical antipsychotics
Malhi, G., Berk, M., Bourin, M., Ivanovski, B., Dodd, S., Lagopoulos, J., & Mitchell, P. B. (2005) · Acta Psychiatrica Scandinavica Supplementum · doi:10.1111/j.1600-0447.2005.00524.x · Cited by 32
Management of atypical antipsychotic‐induced weight gain in schizophrenic patients with topiramate
Lin, Y., Liu, C., & Hsiao, M. (2005) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2005.01424.x · Cited by 32
“Moreover, topiramate reduced the bodyweight and BMI of bipolar patients whose weight gain was due to mood stabilizers or antipsychotics.(7) However, very few reports show the efficacy of topiramate for weight loss in schizophrenic patients,(8) and there is no report about its effect on Asian patients.”
BackgroundKirov, G., & Tredget, J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-19 · Cited by 28
“Background Psychiatric patients who receive long-term mood-stabilizing agents can gain excess body weight [1-3].”
BackgroundBipolar depression: a new role for atypical antipsychotics?
Keck, P. E. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00213.x · Cited by 23
Neurogenesis and Neuroenhancement in the Pathophysiology and Treatment of Bipolar Disorder
Schloesser, R. J., Chen, G., & Manji, H. K. (2006) · International review of neurobiology · doi:10.1016/s0074-7742(06)77005-2 · Cited by 25
Miller, J. C., Jiménez, P., & Mathé, A. A. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007279 · Cited by 19
“These data are consistent with previous studies in rats (Gilmor et al., 2003 ; Seggie et al., 1982) but are not in agreement with findings in humans where weight gain has been reported to be associated with lithium maintenance therapy (Nemeroff, 2003 ; Vestergaard et al., 1988).”
ResultNovel substituted tetrahydrotriazaacenaphthylene derivatives as potent CRF1 receptor antagonists
Gentile, G., Fabio, R. D., Pavone, F., Sabbatini, F. M., St‐Denis, Y., Zampori, M. G., Vitulli, G., & Worby, A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.077 · Cited by 18
Biton, V. (2006) · The Neurologist · doi:10.1097/01.nrl.0000202599.21758.9a · Cited by 19
“While the actual rate of noncompliance resulting from AED-induced weight gain is rather poorly studied, researchers have noted the association between weight gain and noncompliance.(11,12) Moreover, noncompliance with AEDs has been shown to increase seizures.”
ResultSaavedra, J. M., & Pavel, J. (2005) · Drug Development Research · doi:10.1002/ddr.20027 · Cited by 18
Hsieh, M. H., Tang, C., Hsieh, M. H., Lee, I. H., Lai, T. J., Lin, Y.-J., & Yang, Y. K. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.02.038 · Cited by 14
Weight gain with add‐on second‐generation antipsychotics in bipolar disorder: a naturalistic study
Najar, H., Joas, E., Kardell, M., Pålsson, E., & Landén, M. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12737 · Cited by 13
“Several drugs used to treat bipolar disorder have also been associated with weight gain such as antidepressants (12), mood stabilizers (13), and second-generation antipsychotics (SGAs) (13).”
BackgroundSeo, H., Jung, Y., Woo, Y. S., Jun, T., Chae, J., & Bahk, W. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1001 · Cited by 12
Use of asenapine in clinical practice for the management of bipolar mania
Young, A. H., Altamura, A. C., González-Pinto, A. M., Millet, B., & Wiedemann, K. (2013) · Journal of Psychopharmacology · doi:10.1177/1359786813482534 · Cited by 12
“Weight gain not only has a detrimental impact on health, but is also a major driver of non-adherence and consequently an important barrier to effective treatment (Henderson, 2007; Nemeroff, 2003; Torrent et al., 2008).”
BackgroundDiffering psychotropic profiles of the anticonvulsants in bipolar and other psychiatric disorders
Post, R. M. (2004) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2004.06.003 · Cited by 14
Sansone, R. A., & Sansone, L. A. (2011) · PubMed Central · Cited by 9
Novel Treatment Approaches for Refractory Anxiety Disorders
Pollack, M. H., Otto, M. W., Roy‐Byrne, P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.4.foc486 · Cited by 9
Provencher, M. D., Bélanger, M., Shriqui, C. L., Lachance, I., & Bonneville, S. (2016) · L Encéphale · doi:10.1016/j.encep.2016.01.006 · Cited by 9
Safety Considerations in Pharmacotherapy of Bipolar Disorder
Masand, P. S., Fazal, F. S., & Patkar, A. A. (2004) · CNS Spectrums · doi:10.1017/s1092852900028856 · Cited by 9
Practical considerations for carbamazepine use in bipolar disorder
Fuller, M. A., Dostrow, V., Gupta, S., & Gazda, T. D. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.4.501 · Cited by 9
“However, a number of medications commonly used to treat the condition can exacerbate the problem [24-26].”
BackgroundGentile, S. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4167 · Cited by 8
“non-compliance with treatment regimens and, thus, increased risks of symptomatologic relapse.(24,25) Notwithstanding this”
Brown, M., & Shirley, J. L. (2005) · Holistic Nursing Practice · doi:10.1097/00004650-200511000-00009 · Cited by 7
Depression mood stabilisation: novel concepts and clinical management
Calabrese, J. R. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.03.002 · Cited by 7
Reed, C. R., Kalnik, M. W., Rakin, K., Athanasiou, M., & Judson, R. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.2.95 · Cited by 7
Hintermann, S., Hurth, K., Nozulak, J., Tintelnot‐Blomley, M., Aichholz, R., Blanz, J., Kaupmann, K., & Mosbacher, J. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.107 · Cited by 7
Outhred, T., McAulay, C., Gessler, D., & Malhi, G. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32480-7_19 · Cited by 7
Psychotropic-Induced Weight Gain: Liability, Mechanisms and Treatment Approaches
McIntyre, R. S., Konarski, J. Z., & Keck, P. E. (2006) · CRC Press eBooks · doi:10.3109/9780849374517.014 · Cited by 6
P2X7 in Bipolar and Depressive Disorders
Barron, M. L., Werry, E. L., McGregor, I. S., & Kassiou, M. (2013) · Springer eBooks · doi:10.1007/978-3-642-40282-1_31 · Cited by 6
Tercer Consenso Argentino sobre el manejo de los Trastornos Bipolares. Segunda Parte B
Cetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i160.459 · Cited by 5
Lipid Connection to Bipolar Disorder
Azab, A. N., & Greenberg, M. L. (2006) · Future Neurology · doi:10.2217/14796708.1.4.505 · Cited by 3
“Therefore, these drugs are far from perfect medications and they are ineffective for, and not tolerated by, a significant percentage of patients [7,8].”
BackgroundBélanger, M.-È., Provencher, M. D., & Shriqui, C. L. (2013) · Santé mentale au Québec · doi:10.7202/1019188ar · Cited by 4
“Ceux-ci sont aussi à risque de gain pondéral et de complications métaboliques que les patients avec un diagnostic de trouble psychotique, traités principalement avec des antipsychotiques atypiques (Aronne et Segal, 2003 ; Roy Chengappa et al., 2002 ; Nemeroff, 2003 ; Zimmermann et al., 2003).”
BackgroundPhysical Comorbidities and Mood Disorders in Older Adults
Dols, A., & Sonnenberg, C. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-2414-6_15 · Cited by 2
Azab, A. N., & Greenberg, M. L. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00351.x · Cited by 3
Correlation between metabolic syndrome and serum ghrelin levels in bipolar patients
Kalenderoğlu, A., SAVAS, H. A., Gergerlioğlu, H. S., Başaralı, K., Yumru, M., Selek, S., Büyükbaş, S., & Ergene, N. (2010) · Nöro Psikiyatri Arşivi · Cited by 2
Anxiolytics: An In-Depth Review of Contemporary and Emerging Treatment Approaches
Singhal, D., Sharma, N., Paul, S., & Bhatt, S. (2024) · International Journal of Newgen Research in Pharmacy & Healthcare · doi:10.61554/ijnrph.v2i2.2024.129 · Cited by 2
Bereda, G. (2026) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70141 · Cited by 1
Adverse effects and nonadherence with mood stabilizers
Mago, R., Mahajan, R., & Borra, D. (2013) · Journal of Mood Disorders · Cited by 1
Modulation of ion channels in clinical psychopharmacology: adults and younger people
Sinclair, L. I., Dineen, P., & Malizia, A. L. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.21 · Cited by 1
Bipolar Hastalarda Serum Ghrelin Seviyeleri ve Metabolik Sendrom Arasındaki İlişki
Kalenderoğlu, A., SAVAS, H. A., Gergerlioğlu, H. S., Başaralı, K., Yumru, M., Selek, S., Büyükbaş, S., & Ergene, N. (2010) · Nöro Psikiyatri Arşivi · doi:10.4274/npa.y5648 · Cited by 1
Konsoula, Z. (2010) · CRC Press eBooks · doi:10.3109/9781420092264-14 · Cited by 1
Sorokin, O. V., Markova, E. V., Kozhevnikov, V. S., Abramov, V. V., & Козлов, В. А. (2007) · Human Physiology · doi:10.1134/s036211970704007x
Milano, W., Rosa, M. D., Milano, L., Nolfe, G., Petrella, C., Ingenito, A., & Capasso, A. (2012) · Current Neurobiology
ikiuçlu Hastalarda Serum Ghrelin Seviyeleri ve Metabolik Sendrom Aras›ndaki ‹liflki
Kalendero, A., SAVAfi, H. A., BAfiARALI, K., Yumru, M., Selek, S., & Ergene, N. (2010)
Hascoët, M., & Bourin, M. (2011) · Neuromethods · doi:10.1007/978-1-61779-313-4_8 · Cited by 4
Physical Comorbidities and Mood Disorders in Older Adults
Dols, A., & Sonnenberg, C. (2016) · Mental health and illness worldwide · doi:10.1007/978-981-10-0370-7_15-1
Investigating susceptibility to bipolar disorder, migraine and epilepsy
Knott, S. (2016) · ORCA Online Research @Cardiff (Cardiff University)
Lam, D. H., Jones, S. H., & Hayward, P. (2010) · Wiley eBooks · doi:10.1002/9780470970256.refs
Clinical studies on long-term lithium treatment and kidney failure
Aiff, H. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Metadata
- Authors
- Nemeroff, C. B.
- Affiliations
- Emory University (US)
- Corresponding author
- Nemeroff, Charles B.
- ORCID
- Nemeroff, Charles B.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-05-15
- Volume
- 64
- Issue
- 5
- Pages
- 532-539
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2094246063
- Cited by
- 86
- References
- 55
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2014: 2 · 2013: 6 · 2012: 3
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar disorder, drug safety, lithium, atypical antipsychotics, weight gain, medication adherence, tolerability, weight loss, relapse prevention
- MeSH terms
- Topiramate, Anticonvulsants, Bipolar Disorder, Clinical Protocols, Female, Fructose, Humans, Lithium, Obesity, Patient Compliance, Patient Education as Topic, Antipsychotic Agents, Weight Gain, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.